中华皮肤科杂志 ›› 2013, Vol. 46 ›› Issue (3): 185-186.

• 研究报道 • 上一篇    下一篇

血必净联合阿维A治疗红皮病性银屑病24例

唐志铭1,荆梦晴1,翟晓翔2,张翠侠3,李敬果1,4   

  1. 1. 徐州市中医院
    2. 江苏省徐州市中医院，徐州，221000
    3. 徐州市中医院皮肤科
    4.
  • 收稿日期:2012-04-23 修回日期:2012-08-04 出版日期:2013-03-15 发布日期:2013-03-01
  • 通讯作者: 唐志铭 E-mail:158914788@qq.com

Xuebijing injection combined with oral acitretin for the treatment of 24 cases of erythrodermic psoriasis

  • Received:2012-04-23 Revised:2012-08-04 Online:2013-03-15 Published:2013-03-01

PDF

2

赞

摘要： 目的 探讨血必净联合阿维A治疗红皮病性银屑病的临床疗效。 方法 48例红皮病性银屑病患者用随机数字表法分为治疗组和对照组，每组各24例，治疗组采用血必净注射液配合阿维A胶囊治疗，对照组单纯口服阿维A胶囊治疗。治疗8周后进行疗效判定，以银屑病面积与严重度指数（PASI）、有效率、复发率及不良反应等情况为观察指标。结果 治疗组治疗前后PASI差值（34.9 ± 2.2）大于对照组（27.3 ± 1.7），经t检验，差异有统计学意义（t = 3.37，P < 0.05）；治疗组有效率为87.5%，对照组为62.5%，两组差异有统计学意义（χ2 = 4.87，P < 0.05）；治疗组平均起效时间（13.5 ± 2.4 d）较对照组（20.7 ± 3.1 d）明显缩短（t = 3.67，P < 0.05）；治疗组阿维A日均剂量（26.4 ± 3.3 mg）和总用药量（1854.5 ± 85.2 mg）均低于对照组（34.7 ± 3.5 mg和2768.8 ± 88.7 mg），两组差异均有统计学意义（t值分别为3.07和4.32，P < 0.05）。停药随访1年，治疗组有效的21例中，复发2例，复发率为9.5%；对照组有效的15例中，复发4例，复发率为26.6%，两组差异有统计学意义（χ2 = 5.23，P < 0.05）。 结论 血必净与阿维A联用治疗红皮病性银屑病的疗效、起效时间及预后等均明显优于单用阿维A胶囊治疗。

关键词: 银屑病, 阿维A

Abstract: TANG Zhi-ming, JING Meng-qing, ZHAI Xiao-xiang, ZHANG Cui-xia, LI Jing-guo. Department of Dermatology, Xuzhou Hospital of Traditional Chinese Medicine, Xuzhou 221003, Jiangsu, China Corresponding author: TANG Zhi-ming, Email: 158914788@qq.com 【Abstract】 Objective To evaluate the efficacy of Xuebijing injection plus oral acitretin for the treatment of erythrodermic psoriasis. Methods　Forty-eight patients with erythrodermic psoriasis were equally and randomly divided into two groups by a random number table: test group treated with Xuebijing injection once a day plus oral acitretin, and control group treated with oral acitretin. The dose of acitretin began at 0.5 mg per kilogram per day, and was modified according to the tolerance in and response of patients. After 8 weeks of treatment, clinical efficacy was evaluated by psoriasis area and severity index （PASI） score, response rate and recurrence rate. Adverse reactions were also recorded and evaluated. Results The difference in PASI score between pre- and post-treatment was significantly higher in the test group than in the control group （ 34.9 ± 2.2 vs. 27.3 ± 1.7, t = 3.37, P < 0.05）. The total response rate was 87.5% in the test group and 62.5% in the control group （χ2 = 4.87, P < 0.05）. There was a statistical decrease in the average onset time （（13.5 ± 2.4） d vs.（20.7 ± 3.1） d, t = 3.67, P < 0.05）, daily dose and total dose of acitretin （（26.4 ± 3.3） mg vs. （34.7 ± 3.5） mg, （1854.5 ± 85.2） mg vs. （2768.8 ± 88.7） mg, t = 3.07, 4.32, respectively, both P < 0.05） in the test group compared with the control group. The recurrence rate was 9.5% （2/21） in the test group and 26.6% （4/15） in the control group （χ2 = 5.23, P < 0.05）. Conclusion In the case of erythroderma psoriaticum, Xuebijing injection combined with oral acitretin is superior to oral acitretin alone in clinical efficacy, onset time and reducing recurrence.